Compare GSK plc (GSK) vs iShares iBoxx $ High Yield Corporate Bond ETF (HYG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs iShares iBoxx $ High Yield Corporate Bond ETF — how do they compare? GSK plc trades at $52.72 (market cap $101.34B), while iShares iBoxx $ High Yield Corporate Bond ETF trades at $79.79. The key difference: GSK plc pays a 3.49% dividend while iShares iBoxx $ High Yield Corporate Bond ETF pays none, and GSK plc is trading nearer its 52-week high, iShares iBoxx $ High Yield Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| GSK | HYG | |
|---|---|---|
Market Cap | $101.34B | — |
Sector | Health | Fixed Income |
52-Week High | $61.18 | $81.32 |
52-Week Low | $36.20 | $78.72 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
HYG trades at $79.785, up 0.13% with a bearish technical bias from moving averages, while oscillators are neutral. Recent dividends include H1-26 payments of $0.41 and $0.42, and H2-26 at $0.37. News highlights bond ETF inflows and rate hike speculation, with put volume spikes indicating bearish bets on high-yield bonds.
Outlook is cautious due to technical weakness and Fed uncertainty; opportunities exist from yield appeal, but risks include inflation-driven rate hikes and economic slowdowns pressuring corporate debt. Monitor earnings and Fed policy for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →
